Clinical Takeaway
In this small pilot trial of 20 adults with diagnosed insomnia disorder, a single oral dose of 10 mg THC combined with 200 mg CBD reduced total sleep time compared to placebo. These findings suggest that, at least acutely, this cannabinoid combination did not improve objective sleep in this population, and next-day alertness effects were also measured using high-density EEG. Clinicians should be cautious about recommending oral cannabinoids for insomnia based on perceived benefit alone, as objective sleep architecture data may not support subjective impressions of improved sleep.
#9 Acute Effects of Oral Cannabinoids on Sleep and High-Density EEG in Insomnia: A Pilot Randomised Controlled Trial.
Citation: Suraev Anastasia et al.. Acute Effects of Oral Cannabinoids on Sleep and High-Density EEG in Insomnia: A Pilot Randomised Controlled Trial.. Journal of sleep research. 2026. PMID: 40631525.
Design: 5 Journal: 0 N: 0 Recency: 3 Pop: 2 Human: 1 Risk: 0
This pilot study provides the first high-density EEG characterization of how a standardized THC/CBD combination affects sleep architecture and cortical activity in patients with clinically diagnosed insomnia disorder, addressing a critical gap between cannabis’s widespread use as a sleep aid and limited objective neurophysiological evidence. The detailed EEG data on sleep stage progression and next-day alertness will help clinicians distinguish between subjective sleep improvements and actual changes in sleep physiology, informing more evidence-based prescribing decisions for insomnia patients considering cannabinoid therapy.
Methodological Considerations:
- Self-reported outcomes โ recall and social-desirability bias risk
Abstract: Cannabinoids, particularly ฮ9-tetrahydrocannabinol (THC) and cannabidiol (CBD), have gained popularity as alternative sleep aids; however, their effects on sleep architecture and next-day function remain poorly understood. Here, in a pilot trial, we examined the effects of a single oral dose containing 10โmg THC and 200โmg CBD (THC/CBD) on objective sleep outcomes and next-day alertness using 256-channel high-density EEG in 20 patients with DSM-5 diagnosed insomnia disorder (16 female; mean (SD) age, 46.1 (8.6) years). We showed that THC/CBD decreased total sleep time (-24.5โmin, pโ=โ0.05, dโ=โ-0.5) with no change in wake after sleep onset (+10.7 min, pโ>โ0.05) compared to placebo. THC/CBD also significantly decreased time spent in REM sleep (-33.9โmin, pโ<โ0.001, dโ=โ-1.5) and increased latency to REM sleep (+65.6โmin, pโ=โ0.008, dโ=โ0.7). High-density EEG analysis revealed regional decreases in gamma activity during N2 sleep, and in delta activity during N3 sleep, and a regional increase in beta and alpha activity during REM sleep. While there was no observed change in next-day objective alertness, a small but significant increase in self-reported sleepiness was noted with THC/CBD (+0.42 points, pโ=โ0.02, dโ=โ0.22). No changes in subjective sleep quality, cognitive performance, or simulated driving performance were observed. These findings suggest that a single dose of cannabinoids, particularly THC, may acutely influence sleep, primarily by suppressing REM sleep, without noticeable next-day impairment (โฅโ9โh post-treatment). Australian New Zealand Clinical Trial Registry (ACTRN12619000714189) https://www.anzctr.org.au/.
๐ด This pilot study offers useful objective data on cannabinoid effects on sleep architecture in insomnia patients, showing that a single dose of THC/CBD altered EEG patterns in ways consistent with sedation, yet the small sample size (n=20), single-dose design, and lack of longer-term follow-up limit our ability to draw conclusions about sustained efficacy or tolerance development. The unusually high CBD-to-THC ratio (20:1) and predominance of female participants may not generalize to typical cannabis users or diverse patient populations, and we cannot yet determine whether observed EEG changes translate to clinically meaningful improvements in daytime function or quality of life. Additionally, the study does not address potential next-night rebound insomnia or interactions with other sedating medications commonly used in this population. For practitioners considering cannabinoids in insomnia, this work supports the value of objective sleep monitoring but suggests we should counsel patients that a single positive EEG finding does not establish long-term safety or superiority over
| |